SCHEMBL25754913

SCHEMBL25754913

CCOC(=O)Cc1ccc([N+](=O)[O-])cc1S(=O)(=O)Nc1ccc(Cl)cc1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 7/20 0.52
PLA2G1B P04054 1/20 0.46
ATG4B Q9Y4P1 1/20 0.46
LMNA P02545 2/20 0.45
MEN1 O00255 5/20 0.45
KMT2A Q03164 5/20 0.45
HTT P42858 2/20 0.45
MAPT P10636 3/20 0.44
GAA P10253 2/20 0.44
NHERF1 O14745 1/20 0.43
MCL1 Q07820 1/20 0.43
TP53 P04637 1/20 0.43
ALDH1A1 P00352 1/20 0.43
ALOX12 P18054 1/20 0.43
FLT1 P17948 1/20 0.43
FLT4 P35916 1/20 0.43
KDR P35968 1/20 0.43
TBXA2R P21731 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23833760 0.92 MEN1 (0.48) LMNAMEN1KMT2AHTTMAPT
SCHEMBL25754910 0.90 NHERF1 (0.48) IDH1LMNAMEN1KMT2AHTT
SCHEMBL25754707 0.85 MAPT (0.54) IDH1PLA2G1BATG4BMEN1KMT2A
SCHEMBL25759510 0.83 MAPT (0.47) IDH1LMNAMEN1KMT2AMAPT
SCHEMBL7580547 0.78 IDH1 (0.71) IDH1NHERF1MCL1FLT1FLT4
SCHEMBL9080129 0.77 MAPT (0.52) LMNAMEN1KMT2AHTTMAPT
SCHEMBL25754907 0.77 IDH1 (0.48) IDH1PLA2G1BATG4BLMNAMEN1
SCHEMBL25754762 0.77 KMT2A (0.50) IDH1LMNAMEN1KMT2AMAPT
SCHEMBL4271172 0.76 POLB (0.51) LMNAMEN1KMT2AHTTMAPT
SCHEMBL25754726 0.74 IDH1 (0.61) IDH1LMNAHTTTP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-06-08 US disclosed
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, TP53BP1 IDH1 442/4885PLA2G1B 4013/4885ATG4B 2262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.